Cardiome Begins Phase I Study of GED-aPC

Canadian drug company Cardiome Pharma has started dosing in its Phase I study of GED-aPC, which has the potential to treat several cardiovascular diseases.

The single-blind, placebo-controlled, dose-ranging study will measure the safety, tolerability, pharmacokinetics and pharmacodynamics of GED-aPC in 24 healthy subjects. Each subject will receive a 15-minute loading dose at the start of a 24-hour continuous IV infusion of GED-aPC.

Results from this study are expected in the first half of 2008, according to Cardiome.